Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient

Sam, Cenita J.; Desai, Poorvi; Laber, Damian A.; Patel, Ajay M.; Visweshwar, Nathan; Jaglal, Michael

doi:10.1111/tme.12407

Cited by 19 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two of these 6 articles were excluded because the diagnosis of TTP was not confirmed by measurement of ADAMTS13 activity or by occurrence of relapse. Among the 4 included articles, the diagnosis of TTP was supported by ADAMTS13 activity ,5% in 3 [5][6][7] and by the description of relapse in 1 8 (Table 2). …”

Section: Resultsmentioning

confidence: 99%

Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah’s Witness experience

2017

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah’s Witness experience

2017

View full text Add to dashboard Cite

show abstract

“…However, this presents a unique challenge in individuals who are unable to accept plasma due to religious beliefs. With Jehovah's Witnesses, there have been 8 published case reports discussing the successful management of TTP (7 idiopathic, 1 drug related) without the use of TPE (2)(3)(4)(5)(6)(7)(8)(9). There is likely a publication bias with only successful cases being reported.…”

Section: Introductionmentioning

confidence: 99%

Successful Management of Thrombotic Thrombocytopenic Purpura in a Jehovah’s Witness: An Individualized Approach With Joint Decision-Making

Lim

Greenberg

2019

Journal of Patient Experience

View full text Add to dashboard Cite

The management of thrombotic thrombocytopenic purpura (TTP) presents a unique challenge in individuals who are unable to accept plasma due to religious beliefs, given that therapeutic plasma exchange (TPE) is the standard of care. A 61-year-old Jehovah’s Witness woman presented to our hospital with neurological symptoms and laboratory findings suggestive of TTP. On admission, she refused transfusion of blood products, specifically red blood cells, platelets, and plasma but accepted albumin and intravenous immunoglobulin (IVIG); fractions of plasma. She was started on steroids, IVIG, and TPE with albumin as replacement therapy with minimal improvement. After a detailed discussion with the patient and family, they agreed to accept cryosupernatant. The patient started TPE with cryosupernatant for replacement therapy, which resulted in clinical improvement. This case highlights the importance of an individualized approach with joint decision-making given the significant heterogeneity that exists in Jehovah’s Witnesses’ attitude toward the receipt of blood products.

show abstract

“…To our knowledge, there have been only five published case reports of Jehovah's Witnesses whose diagnosis of aTTP is confirmed or considered likely (Table ) . Of the eight episodes in these five and our case, plasma exchange with human albumin solution as the replacement fluid was performed in five episodes.…”

Section: Discussionmentioning

confidence: 70%

Survival of a Jehovah's Witness with thrombotic thrombocytopenic purpura without using plasma: A case report and review of the literature

Baseri

Vishwanathan

Benasher

et al. 2019

J of Clinical Apheresis

View full text Add to dashboard Cite

Acquired thrombotic thrombocytopenic purpura (aTTP) is a serious disorder with arteriolar and capillary thrombosis for which the treatment usually requires plasma exchange with plasma as the replacement fluid. Management of patients who do not accept blood products is a serious challenge. We present the case of a Jehovah's Witness patient who achieved clinical response after treatment with plasma exchange using human albumin solution as the replacing fluid, high dose corticosteroids, and rituximab. The patient also received ADAMTS13 containing plasma cryoprecipitate and von Willebrand factor VIII concentrates. She had an exacerbation of her TTP in less than 3 weeks. She was treated with further plasma exchange with human albumin solution as the replacement fluid, high dose steroids, and rituximab. Bortezomib and N-acetylcysteine were added. The patient eventually improved clinically and achieved remission that is ongoing for more than 7 months. A review of the literature shows that all five previously reported cases of aTTP in Jehovah's Witnesses survived although none received plasma. Two were not even treated with plasma exchange. The experience of this case and those in the literature demonstrates that remission of aTTP may be achieved without using plasma or plasma exchange.

show abstract

Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient

Abstract: We report the first case of TTP in a Jehovah's Witness that was successfully managed with the use of pegylated bovine carboxyhaemoglobin as an adjunct medication.

Cited by 19 publications

References 13 publications

Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah’s Witness experience

Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah’s Witness experience

Successful Management of Thrombotic Thrombocytopenic Purpura in a Jehovah’s Witness: An Individualized Approach With Joint Decision-Making

Survival of a Jehovah's Witness with thrombotic thrombocytopenic purpura without using plasma: A case report and review of the literature

Contact Info

Product

Resources

About